Work

Supplementary Table 3 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Year: 2025

Type: supplementary-materials

Abstract: Supplementary Table 3: All actionable alteration found in PDXs.

DOI: 10.1158/1535-7163.30028642

Authors: Kaushik Varadarajan, Christian X. Cruz Pico, Kurt W. Evans, Maria Gabriela Raso, Yasmeen Qamar Rizvi, Xiaofeng Zheng, Dhruv Chachad, Timothy P. DiPeri, Bailiang Wang, Stephen M. Scott, Ming Zhao, Argun Akcakanat, Antje M. Wengner, Timothy A. Yap, Funda Meric-Bernstam

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4413905971

Cites:

Cited by:

Related to: 10